Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxytocin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR known ✓ | P30559 | 12/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 6/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 5/20 | 1.00 |
| ▸ | AVPR1B | P47901 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxytocin SCHEMBL1173243 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL21527573 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL14085374 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL20707334 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL29048 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL16373316 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL2126148 | 0.98 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL5110121 | 0.98 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL1661474 | 0.98 | OXTR (0.96) | OXTRAVPR1AAVPR2AVPR1B | |
| SCHEMBL19303330 | 0.98 | OXTR (0.96) | OXTRAVPR1AAVPR2AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. | 2008-11-06 | — | — | US | disclosed |
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. | 2008-11-06 | — | — | US | disclosed |
| US-7407949-B2 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2008-08-05 | — | — | US | disclosed |
| WO-2003016316-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | AVPR1A, AVPR2, AVPR1B | OXTR 4/4885AVPR1A 1/4885AVPR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.